The company states: “Eli Lilly (LLY) and Scorpion Therapeutics announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kalpha inhibitor program STX-478. STX-478 is a once-daily oral, ...

Eli Lilly said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to ...

Scorpion Therapeutics Inc. is selling its lead drug in testing for breast cancer and other advanced solid tumors, to Eli ...

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in ...

Eli Lilly plans to acquire Scorpion's PI3Kα program for $2.5 billion, reinvesting Mounjaro and Zepbound profits to expand its ...

The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors.

US pharma major Eli Lilly is to buy the PI3Kα inhibitor program STX-478 from Scorpion Therapeutics, a private US biotech developing small molecule precision oncology therapies.

H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on RLAY stock, giving a Buy rating yesterday.Stay Ahead of the ...

Potential antitrust deregulation could foster a more favourable environment for larger M&A deals, though skepticism remains.

J&J announces a big deal to acquire neuroscience company ITCI for $14.6 billion, while Lilly and GSK announce smaller deals.

Eli Lilly said on Monday it would buy cancer therapy developer Scorpion Therapeutics for up to $2.5 billion in cash. Lilly will acquire Scorpion's experimental oral therapy, STX-478, which is ...

Lilly will acquire Scorpion's experimental oral therapy, STX-478, which is currently being tested in early-stage trials for ...